Organon Beats On Q1, Women's Health Leads the Charge
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
- Organon & Co Financial Performance: Reported a 5% Y/Y increase in Q1 2024 revenue to $1.622 billion, beating consensus.
- Revenue Breakdown: Women’s Health revenue increased by 11%, Biosimilar revenue surged by 46%, and Established Brands remained flat Y/Y.
- Margins and Earnings: Adjusted gross margin was 62.1%, adjusted EBITDA margin contracted to 33.2%, and adjusted EPS was $1.22.
- Financial Position: Cash and cash equivalents were $575 million, debt stood at $8.7 billion, and a quarterly dividend of $0.28 per share was declared.
- Guidance and Stock Performance: FY24 revenue forecast of $6.2-$6.5 billion, reaffirmed adjusted EBITDA margin, and OGN shares were up 2.18% at $19.24.
Analyst Views on XPH
Wall Street analysts forecast XPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XPH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 57.510
Low
Averages
High
Current: 57.510
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
